Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Significant Decline in Short Interest

Repare Therapeutics Inc. (NASDAQ:RPTX) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 609,900 shares, a drop of 18.6% from the October 31st total of 749,700 shares. Based on an average trading volume of 116,000 shares, the short-interest ratio is currently 5.3 days. Approximately 2.1% of the shares of the company are sold short.

Institutional Trading of Repare Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC raised its position in shares of Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock valued at $29,000 after purchasing an additional 7,800 shares during the period. Vontobel Holding Ltd. raised its position in shares of Repare Therapeutics by 20.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after purchasing an additional 4,000 shares during the period. XTX Topco Ltd bought a new stake in shares of Repare Therapeutics during the 2nd quarter valued at $110,000. Exchange Traded Concepts LLC raised its position in shares of Repare Therapeutics by 21.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after purchasing an additional 8,809 shares during the period. Finally, Stifel Financial Corp raised its position in shares of Repare Therapeutics by 36.4% during the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after purchasing an additional 13,800 shares during the period. 85.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a research report on Friday, November 8th.

Repare Therapeutics Price Performance

Shares of RPTX stock opened at $3.28 on Monday. The company has a market capitalization of $139.44 million, a price-to-earnings ratio of -1.64 and a beta of 0.72. Repare Therapeutics has a one year low of $2.71 and a one year high of $8.49. The company’s fifty day moving average price is $3.38 and its 200-day moving average price is $3.37.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.